It’s only fair to share… Cofrogliptin HSK 7653 (2R,3S,5R,6S)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)-6-(trifluoromethyl)oxan-3-amine APPROVALS 2024, CHINA 2024, Haisco Pharmaceutical Group Co, Beichangping, DIABETES Cofrogliptin (developmental name HSK7653) is a long-acting DPP4 inhibitor dosed once every two weeks.[1][2][3][4] Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 …